QUÉBEC CITY, May 8, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:
AEZS) (TSX: AEZ) (the "Company") announces the results of the vote on
directors held earlier today at its annual meeting of shareholders.
Issuers listed on the Toronto Stock Exchange are required to issue a
news release providing this information.
Each of the director nominees proposed by management for election was
elected as director, without a vote by ballot being conducted. The
Company received proxies with regard to voting on the seven directors
nominated for election as set forth in the table below:
|Name of Nominee||Votes For||%||Votes Withheld||%|
|David A. Dodd* ||
|José P. Dorais||
|(*) ||The results for the proxies received regarding Mr. Dodd were originally
received for the Company's former President and Chief Executive Officer
and director, Prof. Juergen Engel. As announced by the Company on April
15, 2013, Mr. Dodd succeeded to Prof. Engel as President and Chief
Executive Officer, and Mr. Dodd was also concurrently appointed to the
Board of Directors. At the same time, the Company announced that
Mr. Dodd would be one of the management director nominees for election
at the Company's annual meeting of shareholders and that Management
proxy holders intended to exercise the discretion granted in the
proxies to vote in favour of the election of Mr. Dodd as a director at
the shareholders' meeting.|
All other matters at the shareholders' meeting, namely the renewal of
and amendment to the Company's Stock Option Plan, the reconfirmation
and approval of the Shareholder Rights Plan and the confirmation of an
amendment to the Company's bylaws, were also approved by shareholders.
About Aeterna Zentaris
Aeterna Zentaris is an oncology and endocrinology drug development
company currently investigating treatments for various unmet medical
needs. The Company's pipeline encompasses compounds at all stages of
development, from drug discovery through to marketed products. For more
information please visit www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.